Less than 1m read
Drugmaker Hikma Pharmaceuticals Plc on Friday said its revenue for the full-year would be between $2.0 billion-$2.1 billion at constant currency, reflecting delays in the launch of its generic asthma drug.
The company's generic version of GlaxoSmithKline's blockbuster lung drug Advair had been denied approval by U.S. regulators due to "major" issues with its application earlier this month.
Hikma had earlier forecast full-year revenue to be around $2.2 billion at constant currency. Revenue from the generics business is now expected to be $670 billion, down from its earlier forecast of $800 million.
(Reporting by Sanjeeban Sarkar in Bengaluru; Editing by Sunil Nair). Copyright (2017) Thomson Reuters. This article was from Reuters and was legally licensed through the NewsCred publisher network. Please direct all licensing questions to firstname.lastname@example.org.
Free Newsroom email alerts
Register for daily/weekly email alerts with news from The Financial Times, Forbes, Reuters, The Economist and more.